NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a
nanomedicines company developing drugs that viruses would not
readily escape, will ring The Opening Bell® at the New York Stock
Exchange (NYSE) on Wednesday, August 13, 2014, tomorrow.
NanoViricides began trading on NYSE MKT as of September 25,
2013.
The event will be webcast on Livestream beginning at 09:26am via
the url http://new.livestream.com/NYSE.
“We are proud to ring The Opening Bell on behalf of our team and
investors to celebrate our new cGMP manufacturing capability that
enables us to move our drug development programs into the clinic
rapidly,” said Anil R. Diwan, PhD, President and Chairman of the
Company.
“Listing on NYSE MKT has enabled us to raise substantial levels
of financing because of which we are now able to restart important
R&D programs such as Ebola,” said Dr. Eugene Seymour, MD, MPH,
CEO of the Company, adding, “Now we also have the ability to
manufacture sufficient quantities of our nanoviricides drugs for
small outbreaks such as the current Ebola outbreak in Africa or the
MERS outbreak in the Mid-East.”
Dr. Seymour and Dr. Diwan will be joined by other members of the
management team and board of directors at the event. In addition to
the live webcast, photos and video of the NYSE bell ringing will
also be available, courtesy of the NYSE, on Facebook (NYSE),
Twitter (@NYSE and @NYSECam), and YouTube (nysetv1).
The Company’s first drug candidate, NV-INF-1, Injectable
FluCide™, is designed to treat all influenza infections in
hospitalized patients. The Company has a rich pipeline comprising
six drug candidates with proven effectiveness against commercially
important diseases. These include Injectable FluCide™, Oral
FluCide™ for out-patients, DengueCide™ for Dengue Severe Syndrome
and Dengue Hemorrhagic Fever, HIVCide™, a potential “functional
cure” for HIV/AIDS, HerpeCide™ skin cream for oral and genital
herpes, and nanoviricide® eye drops for viruses infecting the eye
including conjunctivitis and keratitis causing viruses. In
addition, the Company has R&D programs in diseases of important
global public health impact such as Rabies, MERS, and Ebola. All of
the Company’s programs are in pre-clinical stages, with NV-INF-1 in
IND-enabling studies.
The Company’s nanoviricide nanomedicine platform technology has
been designed for extremely high effectiveness as well as
safety.
The Company’s drugs are based on our biomimetic nanoviricide®
platform. A virus-binding ligand is developed to copy the binding
site of the virus on the cell surface. A number of ligands are
chemically attached into each polymer chain of our nanomicelle
backbone polymer. The resulting nanoviricide forms micelles in
solution that would “look like” the cell surface to the virus. The
virus is expected to bind to it, and the nanomicelle is then
thought to engulf the virus, and possibly also to destroy it.
A Virus is not expected to escape a well designed nanoviricide
drug because any mutations that allow this to happen would also
reduce the ability of the virus to bind to the cell and cause
infection.
This biomimicry would also result in nanoviricide drugs that are
effective against most if not all viruses of a given kind, making
them broad-spectrum antivirals. For example FluCide™ has been shown
to be effective against both Type I and Type II influenza viruses,
and is expected to be effective against bird flu (H5N1), high path
viruses, pandemic and epidemic influenzas, as well as the seasonal
influenza viruses. This is because the ligand in FluCide mimics
sialic acid, the natural receptor for all influenza viruses.
The Company currently has approximately $41 million cash-in-hand
and cash-like-instruments. These funds are estimated to be
sufficient for taking at least one of our drug candidates through
initial human clinical trials, and possibly take another drug
candidate into human clinical trials.
NanoViricides, Inc. now has its own drug manufacturing facility
that is capable of producing sufficient quantities of an anti-Ebola
drug after it is developed, for combating future Ebola epidemics.
This highly customizable nanomedicines cGMP capable pilot scale
manufacturing facility will be able to supply all of the
nanoviricides drug candidates in quantities needed for human
clinical trials.
Thus, NV-INF-1, Injectable FluCide™, has demonstrated
unparalleled effectiveness and safety in animal models. Influenza A
H1N1 infected animals treated with FluCide survived the full 21-day
observation period, whereas animals treated with 40mg/kg/d
oseltamivir phosphate (Tamiflu®) survived only 8 days in this
highly lethal study. NV-INF-1 demonstrated an unparalleled
1,000-fold reduction in lung viral load compared to untreated
animals on day 4 in this lethal animal model study. Moreover, the
lung viral load remained suppressed to this baseline level. In
contrast, the current standard of care, oseltamivir, (Tamiflu®,
Roche) exhibited only a 2-fold reduction in lung viral load at day
4, that rapidly rose by approximately 2X on day 7. NV-INF-1 also
caused the lungs of treated animals to remain substantially
healthier than the untreated control or oseltamivir-treated mice.
Further, NV-INF-1 has been found to be extremely safe in
preliminary safety/toxicology studies.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
viral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024